Physician profile
Lori A Firestone
NPI 1922145283
$9,623.87
in general payments reported to CMS, 2019-2025
23 companies · $2,357 in 2025
The $2,357 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,745 · 2022: $1,600 · 2023: $2,025 · 2024: $1,897 · 2025: $2,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,279.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,368.13 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,315.09 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,100.06 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $829.13 | 2021-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $788.73 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $686.66 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $572.52 | 2021-2025 | Spravato |
| Lundbeck LLC | $525.55 | 2021-2025 | Rexulti |
| Abbvie INC. | $454.71 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $440.40 | 2021-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $378.02 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $349.27 | 2021-2022 | |
| Almatica Pharma LLC | $152.90 | 2022-2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $133.49 | 2023-2025 | Quviviq, Quviviq |
| Merck Sharp & Dohme LLC | $76.64 | 2021-2023 | Belsomra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $74.46 | 2021 | |
| Axsome Therapeutics, INC. | $74.42 | 2023-2025 | Auvelity, Sunosi |
| Harmony Biosciences LLC | $66.46 | 2023-2024 | Wakix |
| Bausch Health US, LLC | $61.67 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.28 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $48.73 | 2025 | Exxua |
| Eisai INC. | $45.63 | 2021 | |
| Arbor Pharmaceuticals, INC. | $19.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Firestone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.